Condition
Non-Hodgkin Lymphoma Refractory/ Relapsed
Total Trials
5
Recruiting
5
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (2)
P 3 (1)
Trial Status
Recruiting5
Clinical Trials (5)
Showing 5 of 5 trials
NCT06334991Phase 1RecruitingPrimary
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT07188558Phase 3Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07121946Phase 1RecruitingPrimary
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07283822Phase 2Recruiting
Amping up With PemJAK
NCT07271121Phase 2RecruitingPrimary
Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL
Showing all 5 trials